Background/Aims: Teriflunomide, an inhibitor of pyrimidine synthesis and thus proliferation of activated T and B lymphocytes, is successfully used for treatment of inflammatory disease. Teriflunomide has further been shown to trigger apoptosis of tumor cells and has thus been considered for the treatment of malignancy. In analogy to apoptosis of nucleated cells, erythrocytes may enter suicidal death or eryptosis, which is characterized by cell shrinkage and phospholipid scrambling of the cell membrane with translocation of phosphatidylserine to the erythrocyte surface. Triggers of cell membrane scrambling include energy depletion, oxidative stress and increase of cytosolic Ca 2+ activity ([Ca 2+ ] i ). The present study explored whether teriflunomide modifies eryptosis. Methods: Flow cytometry was employed to estimate phosphatidylserine abundance at the erythrocyte surface from annexin-V-binding, cell volume from forward scatter, and [Ca 2+ ] i from Fluo3 fluorescence. Results: Oxidative stress (60 min exposure to 0.3 mM tert-butylhydroperoxide), energy depletion (removal of glucose for 48 hours), and exposure to the Ca 2+ ionophore ionomycin (1 µM, 60 min) all increased annexin-Vbinding, decreased forward scatter and enhanced Fluo3 fluorescence. Teriflunomide (5 µg/ml) did not significantly influence Fluo3 fluorescence, forward scatter and annexin-V-binding under control conditions but significantly blunted the increase of annexin-V-binding following oxidative stress, energy depletion and ionomycin exposure. Teriflunomide further blunted the increase of Fluo3 fluorescence following energy depletion, but did not significantly interfere with increase of Fluo3 fluorescence following oxidative stress and ionomycin exposure. Conclusion: Teriflunomide is a novel inhibitor of suicidal erythrocyte death.
Introduction
Teriflunomide, the active metabolite of leflunomide [1] [2] [3] [4] , inhibits the enzyme dihydroorotate dehydrogenase required for de novo pyrimidine synthesis [5] [6] [7] and thus compromises proliferation of activated T and B lymphocytes [8] . Teriflunomide induces a shift from Th1 to Th2 T cells [1] and is successfully used for treatment of inflammatory disease, such as rheumatoid arthritis [1, 9, 10] , psoriatic arthritis [1] , and multiple sclerosis [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . Side effects of teriflunomide include increase of liver enzymes, alopecia, diarrhea, influenza, nausea, and paresthesias [6, 12] .
Teriflunomide has been shown to trigger apoptosis of tumor cells [22] [23] [24] [25] [26] and has thus been considered for the treatment of malignancy [25] . The proapoptotic effect of teriflunomide involves oxidative stress, mitochondrial depolarization and caspase activation [22, 23] .
Even though lacking mitochondria and nuclei, key organelles of apoptosis, erythrocytes may enter suicidal cell death or eryptosis [27] . Triggers of eryptosis include activation of Ca 2+ permeable cation channels with increase of cytosolic Ca 2+ concentration ([Ca 2+ ] i ) [28] . The channels are activated by a variety of triggers including oxidative stress [29] . The increase of [Ca 2+ ] i stimulates cell membrane scrambling [27] and activates Ca 2+ -sensitive K + channels [30] with subsequent cell shrinkage due to K + exit, hyperpolarization, Cl -exit and thus cellular loss of KCl with osmotically driven water [31] . Eryptosis is further stimulated by energy depletion [32] and eryptosis frequently precedes hemolysis [33] .
Signaling stimulating eryptosis further includes ceramide [34] , caspases [35] [36] [37] [38] , Janusactivated kinase JAK3 [39] , casein kinase 1α [40, 41] , protein kinase C [32] and p38 kinase [42] . Inhibitors of eryptosis include AMP activated kinase AMPK [28] , cGMP-dependent protein kinase [43] , PAK2 kinase [44] as well as sorafenib [45] and sunitinib [46] sensitive kinases.
The present study tested, whether eryptosis is sensitive to teriflunomide. To this end, the effect of teriflunomide on [Ca 2+ ] i , cell volume and phosphatidylserine abundance at the erythrocyte surface has been determined following oxidative stress, energy depletion, and stimulation of Ca 2+ entry by the Ca 2+ ionophore ionomycin.
Materials and Methods

Erythrocytes, solutions and chemicals
Fresh Li-Heparin-anticoagulated blood samples were kindly provided by the blood bank of the University of Tübingen. The blood was centrifuged at 120 x g for 20 min at 21 °C and the platelets and leukocytes-containing supernatant was disposed. The study is approved by the ethics committee of the University of Tübingen (184/2003V). Erythrocytes were incubated in vitro at a hematocrit of 0.4% in Ringer solution containing (in mM) 125 NaCl, 5 KCl, 1 MgSO 4 , 32 N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES), 5 glucose, 1 CaCl 2 ; pH 7.4 at 37°C for 48 h. Where indicated, energy depletion was accomplished by removal of glucose and teriflunomide (Sigma Aldrich, Hamburg, Germany) was added at the indicated concentrations. In order to estimate the impact of teriflunomide on eryptosis due to high [Ca 2+ ] i or oxidative stress, erythrocytes were exposed for 60 min to a combination of teriflunomide and the Ca 2+ ionophore ionomycin (Merck Millipore, Darmstadt, Germany) or the oxidant tert-butylhydroperoxide (Sigma Aldrich, Hamburg, Germany).
Annexin-V-binding and forward scatter
After incubation under the respective experimental condition, 150 µl cell suspension was washed in Ringer solution containing 5 mM CaCl 2 and then stained with Annexin-V-FITC (1:200 dilution; ImmunoTools, Friesoythe, Germany) in this solution at 37°C for 15 min under protection from light. In the following, the forward scatter (FSC) of the cells was determined, and annexin-V-fluorescence intensity was measured with an excitation wavelength of 488 nm and an emission wavelength of 530 nm on a FACS Calibur (BD, Heidelberg, Germany). A marker (M1) was placed to set an arbitrary threshold between annexin-V-binding cells and control cells. The same threshold was used for untreated and teriflunomide treated erythrocytes. The threshold of forward scatter was set at the default value of "52".
Intracellular Ca
2+
After incubation, erythrocytes were washed in Ringer solution and then loaded with Fluo-3/AM (Biotium, Hayward, USA) in Ringer solution containing 5 mM CaCl 2 and 5 µM Fluo-3/AM. The cells were incubated at 37°C for 30 min. Then, Ca 2+ -dependent fluorescence intensity was measured with an excitation wavelength of 488 nm and an emission wavelength of 530 nm on a FACS Calibur (BD, Heidelberg, Germany). Afterwards, the geometric mean of the Ca 2+ dependent fluorescence was determined.
Statistics
Data are expressed as arithmetic means ± SEM. As indicated in the figure legends, statistical analysis was made using ANOVA with Tukey's test as post-test and t test as appropriate. n denotes the number of different erythrocyte specimens studied. Since batches of erythrocytes may differ in their susceptibility to triggers of eryptosis, the same erythrocyte batches have been used for control and experimental conditions.
Results
The present study explored whether teriflunomide influences the suicidal erythrocyte death or eryptosis, which is characterized by cell membrane scrambling with phosphatidylserine translocation to the outer leaflet of the cell membrane. In order to identify erythrocytes with phosphatidylserine exposed at the cell surface, annexin-Vbinding was quantified utilizing flow cytometry. As a result, following a 48 hours incubation in Ringer solution, the percentage of annexin-V-binding erythrocytes was similar in the Cellular Physiology and Biochemistry absence (0.9 ± 0.1%, n = 18) and in the presence of 5 µg/ml (1.0 ± 0.1%, n = 18) or 10 µg/ ml (1.0 ± 0.1%, n = 19) teriflunomide. Induction of oxidative stress by administration of tert-butylhydroperoxide (60 min, 0.3 mM) was followed by a significant increase of annexin-V-binding, an effect significantly blunted in the presence of teriflunomide (5 and 10 µg/ml) ( Fig. 1) . Eryptosis is further typically paralleled by cell shrinkage. In order to estimate cell volume, forward scatter was determined with flow cytometry. As a result, following a 48 hours incubation in Ringer solution, the forward scatter was similar in the absence of teriflunomide (509.7 ± 7.5 a.u., n = 18) and in the presence of 5 µg/ml teriflunomide (492.3 ± 8.2 a.u., n = 18). The average forward scatter was slightly, but significantly (p<0.05) lower following treatment with 10 µg/ml teriflunomide (481.1 ± 6.8 a.u., n = 19) than in the absence of teriflunomide. As illustrated in Fig. 2 , oxidative stress by a 60 min exposure to 0.3 mM tert-butylhydroperoxide was followed by a significant decrease of erythrocyte forward scatter. The effect of tert-butylhydroperoxide on average forward scatter was not significantly modified by teriflunomide (Fig. 2) . However, teriflunomide decreased the percentage of erythrocytes with large (>600) and small (<200) forward scatter, both effects reaching statistical significance at 10 µg/ml teriflunomide concentration (Fig.2 C,D) . Zierle ] i was estimated from Fluo3 fluorescence. As a result, following a 48 hours incubation in Ringer solution, the Fluo3 fluorescence was similar in the absence (23.0 ± 1.2 a.u., n = 8) and in the presence of 5 µg/ml (22.7 ± 0.9 a.u., n = 8) or 10 µg/ml (22.9 ± 0.9 a.u., n = 8) of teriflunomide. As illustrated in Fig. 3 , oxidative stress by a 60 min exposure to 0.3 mM tert-butylhydroperoxide was followed by a significant increase of [Ca 2+ ] i , which was not significantly modified by additional exposure of erythrocytes to teriflunomide.
Eryptosis could further be triggered by energy depletion. Thus, the effect of teriflunomide was tested in erythrocytes exposed for 48 hours to Ringer with or without glucose. As illustrated in Fig. 4 , the glucose deprivation was followed by a significant increase of the percentage of annexin-V-binding erythrocytes, an effect significantly blunted by the addition of teriflunomide (1 -10 µg/ml). As shown in Fig. 5 , the glucose deprivation was 
further followed by a significant decrease of the average forward scatter, an effect not significantly modified by the addition of teriflunomide (1 -10 µg/ml). As illustrated in Fig.  6 , the glucose deprivation was followed by a significant increase of Fluo3 fluorescence, an effect significantly blunted by the addition of teriflunomide (5 and 10 µg/ml). Additional experiments were performed to test whether teriflunomide influences the effect of [Ca 2+ ] i on cell membrane scrambling and forward scatter. To this end, [Ca 2+ ] i was increased by administration of the Ca 2+ ionophore ionomycin (1 µM). As illustrated in Fig. 7 , a 60 min exposure to ionomycin (1 µM) was followed by a marked increase of the percentage of annexin-V-binding erythrocytes, an effect significantly blunted in the presence of teriflunomide (5 µg/ml). In contrast to the effect of teriflunomide on annexin-V-binding, teriflunomide did not significantly interfere with ionomycin-induced cell shrinkage (Fig. 8) and increase of [Ca 2+ ] i (Fig. 9) .
Discussion
The present study uncovers a novel effect of teriflunomide, i.e. inhibition of erythrocyte cell membrane scrambling, a hallmark of eryptosis, the suicidal erythrocyte death. Treatment of human erythrocytes with 10 µg/ml teriflunomide was without effect on cell membrane scrambling under control conditions, but teriflunomide (5 and/or 10 µg/ ml) significantly interfered with cell membrane scrambling following oxidative stress, energy depletion and Ca 2+ loading with the Ca 2+ ionophore ionomycin. The concentrations required for an inhibitory effect of teriflunomide on cell membrane scrambling were within the range of plasma concentrations encountered in patients following teriflunomide treatment [47] . The present observations do not rule out that higher concentrations exert different effects.
The mechanisms underlying the inhibitory effect of teriflunomide on cell membrane scrambling remained incompletely understood. In nucleated cells, teriflunomide-induced apoptosis involves mitochondria, which are, however, lacking in erythrocytes [22] [23] [24] 48] . Instead, teriflunomide may in part be effective by counteracting oxidative stress [22] and/ or by inhibition of cyclooxygenase [49] both mechanisms contributing to the orchestration of eryptosis [50] .
Oxidative stress has previously been shown to enhance cytosolic Ca 2+ activity ([Ca   2+ ] i ), at least in part by activating Ca 2+ permeable cation channels [29] . Accordingly, oxidative stress increases Fluo3 fluorescence. The increase of [Ca 2+ ] i stimulates cell membrane scrambling [27] and decreases cell volume by activation of Ca 2+ sensitive K + channels [30, 51] leading to K + exit, cell membrane hyperpolarization, Cl -exit and thus cellular loss of KCl, which drives water exit [31] . Teriflunomide inhibited cell membrane scrambling without appreciably modifying the increase of [Ca 2+ ] i . Teriflunomide did not significantly affect the average forward scatter during oxidative stress. However, close inspection of the histogram reveals that teriflunomide decreased the percentage of both, swollen and shrunken erythrocytes. It appears that teriflunomide has a slight shrinking effect but blunts the cell shrinkage induced by oxidative stress.
Teriflunomide further significantly blunted the cell membrane scrambling following energy depletion. The effect of teriflunomide on cell membrane scrambling following energy depletion was paralleled by a similar effect of teriflunomide on [Ca 2+ ] i . Thus, the inhibition of cell membrane scrambling following energy depletion by teriflunomide could at least in part be explained by the effect of teriflunomide on [Ca 2+ ] i . However, teriflunomide significantly blunted the increase of annexin-V-binding following treatment of the erythrocytes with the Ca 2+ ionophore ionomycin, even though teriflunomide did not interfere with ionomycin induced increase of [Ca 2+ ] i and ionomycin induced cell shrinkage. Accordingly, teriflunomide is at least partially effective by interfering with the scrambling effect of increased [Ca 2+ ] i . In view of the present observations, teriflunomide could, at least in theory, be utilized to counteract eryptosis. Eryptosis is stimulated by a wide variety of xenobiotics and is triggered in several clinical disorders [27] , such as diabetes [38, 85, 86] , renal insufficiency [87] , hemolytic uremic syndrome [88] , sepsis [89] , malaria [90] [91] [92] [93] [94] , sickle cell disease [95] , Wilson's disease [93] , iron deficiency [96] , malignancy [97] , phosphate depletion [98] , and metabolic syndrome [99] .
Phosphatidylserine exposing erythrocytes are rapidly removed from circulating blood, and excessive eryptosis could thus lead to anemia [34] . Phosphatidylserine exposing erythrocytes further interfere with microcirculation [100] [101] [102] [103] [104] [105] by adherence to endothelial CXCL16/SR-PSO of the vascular wall [101] , by stimulation of blood clotting and triggering of thrombosis [100, 106, 107] . According to the present observations, teriflunomide could possibly counteract the respective side effects of xenobiotics or complications of diseases associated with excessive eryptosis.
In conclusion, teriflunomide blunts the Ca 2+ entry following energy depletion and the increase of cell membrane scrambling following oxidative stress, energy depletion and increase of cytosolic Ca 2+ concentration by ionophore treatment. These effects have the potential to counteract anemia and/or derangement of microcirculation in conditions with excessive suicidal erythrocyte death.
